Oxeltis is delighted to welcome Christophe Parsy as Director of Business and Strategic Development.
With over 25 years of experience in the pharmaceutical sector—spanning CROs, biotech, and major corporations—Christophe brings deep expertise in anti-infectives (HIV, HCV…), antimicrobials, oncology, and small-molecule chemistry, having contributed to the development of several clinical candidates. His skills encompass small molecules, prodrugs, DNA-encoded libraries, AI-assisted design, Fragment-Based Drug Design (FBDD), and targeted protein degradation.
As former Head of Medicinal Chemistry and Senior Leader of Integrated Drug Discovery at Oncodesign Services, he led preclinical projects, steered strategic alliances, conducted due diligence, and championed the company’s integrated drug discovery capabilities on a global scale. In his new role at Oxeltis, Christophe merges scientific acumen with strategic vision to forge robust partnerships, uncover new opportunities, and solidify the company’s reputation as a leader in early-stage drug discovery—particularly in small molecules, targeted protein degradation, and the complex chemistry of nucleosides/nucleotides. By aligning Oxeltis’ expertise with market and client needs, he is instrumental in driving innovation-led growth, expanding the company’s global reach, and reinforcing its position as a trusted partner in contracted medicinal chemistry research.
